Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.
暂无分享,去创建一个
C. Van Waes | Zhong Chen | J. Friedman | C. Allen | E. Moore | Christopher Silvin | Harrison A. Cash | Paúl E. Clavijo | R. Davis | Ruth J. Davis
[1] J. Kutok,et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.
[2] C. Van Waes,et al. Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade , 2016, Cancer Immunology Research.
[3] Philippe Foubert,et al. PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.
[4] A. V. Nguyen,et al. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. , 2016, Cancer discovery.
[5] Roberto Piñeiro,et al. Inactivation of PI(3)K p110 delta breaks regulatory T-cell-mediated immune tolerance to cancer (vol 510, pg 407, 2014) , 2016 .
[6] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[7] C. Van Waes,et al. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. , 2016, Oral oncology.
[8] D. Vignali,et al. Targeting regulatory T cells in tumors , 2016, The FEBS journal.
[9] C. Van Waes,et al. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers , 2016, Cancer Immunology Research.
[10] Tonya J. Webb,et al. Human Head and Neck Squamous Cell Carcinoma–Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells , 2016, The Journal of Immunology.
[11] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[12] Kevin P. White,et al. Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.
[13] I. Flinn,et al. a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL , 2014 .
[14] J. Califano,et al. Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2014, Clinical Cancer Research.
[15] T. Whiteside. Induced regulatory T cells in inhibitory microenvironments created by cancer , 2014, Expert opinion on biological therapy.
[16] P. Cheng,et al. Macrophage PTEN Regulates Expression and Secretion of Arginase I Modulating Innate and Adaptive Immune Responses , 2014, The Journal of Immunology.
[17] Dalya R. Soond,et al. Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer , 2014, Nature.
[18] T. Karrison,et al. Adoptively Transferred Immune T Cells Eradicate Established Tumors despite Cancer-Induced Immune Suppression , 2014, The Journal of Immunology.
[19] Bonnie Tillotson,et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. , 2013, Chemistry & biology.
[20] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[21] H. Zhang,et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. , 2013, The Journal of clinical investigation.
[22] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[23] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[24] D. Stocken,et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.
[25] Mario Roederer,et al. Interpretation of cellular proliferation data: Avoid the panglossian , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[26] B. Vanhaesebroeck,et al. The emerging mechanisms of isoform-specific PI3K signalling , 2010, Nature Reviews Molecular Cell Biology.
[27] Dalya R. Soond,et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. , 2010, Blood.
[28] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[29] T. Whiteside,et al. A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-β1 Mediates Suppression in the Tumor Microenvironment , 2007, Clinical Cancer Research.
[30] P. Murray,et al. Enhancer-Mediated Control of Macrophage-Specific Arginase I Expression1 , 2004, The Journal of Immunology.
[31] D. Gabrilovich,et al. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. , 2001, Human immunology.
[32] G. Dong,et al. Growth Regulated Oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC Receptor-2 dependent mechanism , 2000, Oncogene.
[33] C. Allen,et al. Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays. , 2017, Journal of immunological methods.
[34] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.
[35] Woe-Yeon Kim,et al. Veratric acid inhibits iNOS expression through the regulation of PI3K activation and histone acetylation in LPS-stimulated RAW264.7 cells. , 2015, International journal of molecular medicine.
[36] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[37] G. Dunn,et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. , 2012, Cancer research.
[38] J. Ryan,et al. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling , 2007, Genes and Immunity.
[39] M. Colombo,et al. The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.
[40] A. S. Pak,et al. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.